Rhythm Pharmaceuticals, Inc. announced the commercial introduction of IMCIVREE® (setmelanotide), a medication intended to help people with Bardet-Biedl syndrome (BBS). BBS is a rare genetic illness that affects between 4,000 and 5,000 people in the European Union and the United Kingdom, with an estimated frequency of 1,200 people in Germany.
People with BBS may have early-life severe obesity as well as hyperphagia or overeating. Hypogonadism, polydactyly, renal failure, visual impairment, and cognitive impairment may also be associated with BBS. The only drug for monogenic and syndromic obesity that has received FDA and EC approval is IMCIVREE®. It is also the only treatment for BBS that has received approval in Germany.
Patients may now obtain IMCIVREE® for the therapy in nine worldwide countries, including the United States.
Image Credit: Rhythm Pharmaceuticals, Inc.
What's Driving This Trend
- BBS Medications
- The approval of IMCIVREE® medication introduces an opportunity for other companies to develop and offer treatments for BBS patients.
- Rare Genetic Illness Treatments
- The development of medication for rare genetic illnesses, such as BBS, presents opportunities for pharmaceutical companies to fill the gap in treatment options.
- Remote/telemedicine
- Telemedicine could improve access to BBS treatment and support for patients who cannot easily visit healthcare providers.
Who This Affects Most
- Pharmaceuticals
- The pharmaceutical industry, particularly those focused on rare diseases, benefit from BBS medication development.
- Telemedicine
- The use of telemedicine could make it easier for healthcare providers to remotely reach patients with BBS.
- Healthcare
- Developments in healthcare technology and treatment options for rare diseases presents opportunities for medical professionals to improve patient care and outcomes.
